Baxter International Inc. acquired Prism Pharmaceuticals for $338 million, with partner Roger Rhoten advising.
Pennsylvania-based Prism Pharmaceuticals is a specialty pharmaceutical company which recently received FDA approval of an antiarrhythmic drug, enhancing Baxter's portfolio of acute care premix drugs.